Next Article in Journal
Cannabinoids and Dementia: A Review of Clinical and Preclinical Data
Next Article in Special Issue
Clinical Toxicities of Histone Deacetylase Inhibitors
Previous Article in Journal
The Role of Cannabinoid Receptors in the Descending Modulation of Pain
Previous Article in Special Issue
Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
Open AccessReview

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies

Cancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Australia
Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Australia
University of Melbourne, Parkville, Melbourne, Australia
Author to whom correspondence should be addressed.
Pharmaceuticals 2010, 3(8), 2674-2688;
Received: 23 July 2010 / Revised: 12 August 2010 / Accepted: 13 August 2010 / Published: 17 August 2010
(This article belongs to the Special Issue HDAC Inhibitors)
Histone deacetylase inhibitors (HDACi) can induce hyperacetylation of both histone and non-histone target resulting in epigenetic reprogramming and altered activity, stability and localisation of non-histone proteins to ultimately mediate diverse biological effects on cancer cells and their microenvironment. Clinical trials have demonstrated single agent HDACi to have activity in hematological malignancies, in particular T-cell lymphoma and Hodgkin lymphoma. Combination strategies with standard therapies based on pre-clinical data are being employed with significant success due to their excellent side effect profile. Correlative studies will provide valuable information on the sub-groups of patients more likely to respond or be resistant to HDACi therapy, while long-term monitoring for toxicities is also needed. View Full-Text
Keywords: Histone deacetylase inhibitors; Clinical studies; Haematology Histone deacetylase inhibitors; Clinical studies; Haematology
MDPI and ACS Style

Bishton, M.J.; Johnstone, R.W.; Dickinson, M.; Harrison, S.; Prince, H.M. Overview of Histone Deacetylase Inhibitors in Haematological Malignancies. Pharmaceuticals 2010, 3, 2674-2688.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop